Management changes at XOMA
This article was originally published in Scrip
Steve Engle, XOMA's chief executive officer, president and chairman has resigned from the company after four years' service. John Varian, a current board member and former COO and CFO of Aryx Therapeutics, will take over as interim CEO during the search for a permanent CEO, and W Denman Van Ness, XOMA's lead independent director, has been elected chairman.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.